Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Other solid neoplasm 3Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Other neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 218Fluorouracil 142Oxaliplatin 132Capecitabine 122pembrolizumab 113Irinotecan 110Leucovorin 104Bevacizumab 98Nivolumab 80Cisplatin 80130-nm albumin-bound paclitaxel 80Cetuximab 79Radiotherapy 78Albumin-Bound Paclitaxel 59Sorafenib 56Paclitaxel 53Cyclophosphamide 50Carboplatin 47Magnetic Resonance Spectroscopy 44Specimen Handling 39Docetaxel 37Taxes 36fludarabine 34Radiation 34durvalumab 33Ipilimumab 33Erlotinib Hydrochloride 33Biopsy 33Radiosurgery 27Folfox protocol 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × ON 01910 × Gastrointestinal × Clear all
NCT00861783 2017-06-23

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Traws Pharma, Inc.

Phase 1 Completed
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡